George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMast Energy. Regulatory News (MAST)

Share Price Information for Mast Energy. (MAST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.475
Bid: 0.45
Ask: 0.50
Change: 0.00 (0.00%)
Spread: 0.05 (11.111%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.475
MAST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MED Acquires two Projects and Secures Funding

5 Oct 2022 07:00

RNS Number : 7891B
Mast Energy Developments PLC
05 October 2022
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

("MED" or "the Company")

 

5 October 2022

Mast Energy Developments Plc ("MED" or "the Company")

 

MED Completes Acquisition of two further Reserve Power Projects and secures associated Funding

 

Mast Energy Developments PLC, the UK-based multi-asset owner and operator in the rapidly growing Reserve Power market, announces today that it has exchanged final documentation and completed ("the Completion") the definitive Sale and Purchase Agreements ("SPA's") to acquire the entire share capital of ARL 018 Limited and ADV 001 Limited (the "SPV's"), two UK companies whose principal assets are the Stather Road ("Stather") and Hindlip Lane ("Hindlip") reserve power projects respectively (the "Projects"). The SPV's were acquired from DKE Flexible Energy Limited (the "Seller"), a wholly owned subsidiary of Dukemount Capital PLC (LON: DKE).

Highlights

· The Projects each comprise a shovel-ready reserve power generation plant with:

Current grid connection capacity of 11 kVA 2.4 MW at Stather and 11kVA 7.5 MW at Hindlip respectively;

Low emissions and carbon tax exempt;

Long-term leasehold properties;

a Grid Connection Offer;

a Gas Connection Offer; and

Planning and permitting already in-place.

· The total purchase consideration for the acquisition of the SPV's and its associated assets and property rights under the SPA's amounts to £350,000 and will be funded by way of a loan arrangement with very competitive commercial terms (see details below), inclusive of a cash payment to the Seller in settlement of an outstanding shareholder loan account amounting to £10,693.60.

· Encora Energy Limited, MED's Owner's Engineer conducted a comprehensive due diligence investigation on the Projects on behalf of the Company and reported an overall positive finding.

· Comprehensive economic and financial modelling performed by MED's leading energy markets data consultant, EnAppSys, with a robust outcome (see further details below).

· Proven and significant market demand with MED's preferred investment grade power purchase off-taker, Statkraft UK already secured, inclusive of the implementation and execution of MED's desired trading and optimization strategy.

· The addition of the Projects will significantly boost MED's Reserve Power portfolio by 54% taking total generation output capacity to 28.3 MW.

Funding Arrangement

The acquisition of the Projects is being funded by way of a loan arrangement led by an institutional investor (the "Investor"), with the following competitive commercial terms:

· Fixed term of up to three years;

· Interest free, with only the principal drawn repayable;

· No warrants;

· Principal loan advance of £350,000 on signing the agreement and used by MED to fund the purchase of the SPVs;

· The Investor may elect to convert some or all of loan amounts outstanding to ordinary shares in the Company at a price per share equal to the average of the five daily Volume Weighted Average Prices ("VWAPs") preceding the drawdown date of the loan advance (the "Reference Price"); and

· Additionally, the Investor may not undertake any conversion within 3 months from the First Tranche drawdown date and may not undertake any Conversion during the first 12 months from the loan advance until the MED share price has closed at 200% (i.e. 2x) of the Reference Price or greater.

Rationale for Projects' Acquisition

The acquisition of Stather and Hindlip marks another important step in MED's ability to deliver on its strategy to build a 300 MW portfolio of Reserve Power projects. The transaction also presented a value opportunity to add to its existing 9 MW operating Pyebridge operation and its two development projects Bordesley and Rochdale (c. 5 MW each), significantly boosting MED's Reserve Power portfolio by 54% taking total generation output capacity to 28.3 MW. The signing of the SPA followed a detailed due diligence by the Company and its technical advisors, Encora Energy Ltd, on a portfolio of projects presented to it.

Based on independent financial modelling, prepared by MED's reputable and appropriately accredited consulting firm, EnAppSys the projected valuation metrics for the Projects are summarised as follows:

· Unlevered Internal Rate of Return ("IRR") base case of c. 15%;

· Projected base case average annual revenue of c. £2.7 million for Hindlip and c. £928k for Stather;

· Operating Profit Margin of 30%; and

· Capital development costs in the region of £1.6 million for Stather Road and £4.5 million for Hindlip Lane.

The Company is confident from the financial modelling to date that with carefully negotiated off-take agreements and optimum use of capacity market contracts, for which both projects can qualify, commercial returns can achieve the upper end or exceed the financial metrics indicated above. It should however be noted that while every care was taken in the Company's financial modelling, figures quoted are preliminary estimates and may change commensurate with risks normally associated with projects of this nature.

The Company will now expedite development of the sites which are currently at shovel-ready status, with construction anticipated to commence before the end of this year and commissioning during 2023.

Pieter Krügel, MED CEO, commented: "We are delighted with the latest acquisitions that bolster MED's growing portfolio of projects and to keep delivering on its main strategy to build a portfolio of 300 MW of Reserve Power projects. The addition of these latest sites to the MED stable will significantly increase its generation output capability to close to c. 30 MW. The acquisitions follow a robust and rigorous assessment and due diligence process to ensure that each project adheres to MED's strict technical and investment criteria, to support the best possible outcome for shareholders.

With increasing supply/demand volatility and the current unprecedented energy crisis globally and in the UK, the Reserve Power market is the fastest growing energy sector in the UK and accordingly there is significant demand for flexible power projects of this kind and at increasingly attractive economics. We are continually seeking and assessing possible next acquisitions with a current pipeline totalling a further c. 100 MW currently under assessment.

We look forward to updating the market with further developments in due course, as we continue to rapidly gain momentum in executing the MED business strategy."

ENDS

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

 Pieter Krügel

info@med.energy

Mast Energy Developments Plc

CEO

 Jonathan Critchley & Keith Swann

+44 (0)20 3869 6080

Clear Capital Markets

Joint Broker

 Zainab Slemang van Rijmenant

zainab@lifacommunications.com

Lifa Communications

Investor and Media Relations Advisor

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZLFBLBLZFBE
Date   Source Headline
26th Apr 20247:00 amRNSBusiness Update
23rd Apr 20242:30 pmRNSHolding(s) in Company TR 1
11th Apr 20247:00 amRNSBusiness Update
7th Mar 20248:06 amRNSQ1 2024 Corporate Presentation
4th Mar 202410:45 amRNSHolding(s) in Company
28th Feb 20247:00 amRNSFunding Partner, Agreement & Proventure Terminated
20th Feb 20241:00 pmRNSTR-1: Standard form notification of major holdings
5th Feb 20241:55 pmRNSTR-1: Standard form notification of major holdings
24th Jan 20243:45 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSMED Binding JVA Progress Update
2nd Jan 20247:00 amRNSMED Binding JVA Completion Update
22nd Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Dec 20237:00 amRNSDirector Loan & PDMR Share Sale
11th Dec 20237:52 amRNSMED Binding JVA Update
11th Dec 20237:00 amRNSMED Binding JVA Completion Update
5th Dec 20234:30 pmRNSHolding(s) in Company
1st Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Nov 20233:31 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSMED Binding JVA Interim Payment Update
26th Oct 202310:54 amRNSHolding(s) in Company
23rd Oct 20237:00 amRNSMED Binding JVA Completion Update
12th Oct 20232:03 pmRNSHolding(s) in Company
12th Oct 20232:01 pmRNSHolding(s) in Company
12th Oct 20232:00 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSIssue of Equity
22nd Sep 20237:00 amRNSMED Binding JVA Completion Update
1st Sep 20237:00 amRNSMED Binding Joint Venture Completion Update
25th Aug 20237:00 amRNSHalf-year Report
9th Aug 20232:16 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSMED Binding Joint Venture Completion Update
12th Jul 20231:15 pmRNSJoint Venture
6th Jun 20231:09 pmRNSResult of AGM
23rd May 20232:30 pmRNSIssue of Equity
22nd May 20233:00 pmRNSShares issue
18th May 20237:00 amRNSJV & Investment. New Broker & Loan Reprofiling
16th May 20231:15 pmRNSNotice of AGM
4th May 20237:00 amRNSQ1 Corporate Presentation and Website Update
28th Apr 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSPyebridge Update
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20222:05 pmRNSSecond Price Monitoring Extn
20th Dec 20222:00 pmRNSPrice Monitoring Extension
16th Dec 20227:00 amRNSPyebridge SPA Deferred Consideration Settlement
15th Dec 20222:00 pmRNSTR-1: Notification of major holdings
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
8th Dec 20227:00 amRNSBordesley Update
17th Nov 20227:00 amRNSCorporate Presentation
3rd Nov 20227:00 amRNSFurther Funding Secured

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.